TY - JOUR
T1 - Kaposi sarcoma inflammatory cytokine syndrome (KICS)
T2 - A rare but potentially treatable condition
AU - Karass, Michael
AU - Grossniklaus, Emily
AU - Seoud, Talal
AU - Jain, Sanjay
AU - Goldstein, Daniel A.
N1 - Publisher Copyright:
© AlphaMed Press 2017.
PY - 2017/5
Y1 - 2017/5
N2 - Kaposi sarcoma inflammatory cytokine syndrome (KICS) is a newly-described condition affecting individuals who are HIV-positive and are infected with human herpesvirus 8 (HHV-8). This is a syndrome that in some ways mimics severe sepsis with associated acute respiratory distress syndrome, possibly requiring a ventilator and vasopressor support. However, unlike severe sepsis, antibiotics provide no benefit. Management of KICS has not been fully elucidated because of its high mortality rate. However, the syndrome has been successfully treated in some cases with immunomodulatory therapy. It is crucial for oncologists to be able to recognize this syndrome and to institute the appropriate therapy.
AB - Kaposi sarcoma inflammatory cytokine syndrome (KICS) is a newly-described condition affecting individuals who are HIV-positive and are infected with human herpesvirus 8 (HHV-8). This is a syndrome that in some ways mimics severe sepsis with associated acute respiratory distress syndrome, possibly requiring a ventilator and vasopressor support. However, unlike severe sepsis, antibiotics provide no benefit. Management of KICS has not been fully elucidated because of its high mortality rate. However, the syndrome has been successfully treated in some cases with immunomodulatory therapy. It is crucial for oncologists to be able to recognize this syndrome and to institute the appropriate therapy.
UR - http://www.scopus.com/inward/record.url?scp=85019094098&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2016-0237
DO - 10.1634/theoncologist.2016-0237
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28424322
AN - SCOPUS:85019094098
SN - 1083-7159
VL - 22
SP - 623
EP - 625
JO - Oncologist
JF - Oncologist
IS - 5
ER -